BIO 205
Alternative Names: BIO-205Latest Information Update: 28 Feb 2024
At a glance
- Originator National Institutes of Health (USA); Saint Louis University
- Developer BioIntervene
- Class Analgesics; Anti-inflammatories; Heterocyclic compounds; Small molecules
- Mechanism of Action Adenosine A3 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Pain in USA (PO)
- 14 Jan 2020 National Institutes of Health (NIH) files PCT application for A3 adenosine receptor (A3AR) agonist worldwide before January 2020
- 14 Jan 2020 National Institutes of Health (NIH) has patent protection for A3 adenosine receptor (A3AR) agonist in USA and China